These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire. Diabaté S; Alary M HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945 [TBL] [Abstract][Full Text] [Related]
26. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314 [TBL] [Abstract][Full Text] [Related]
27. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397 [TBL] [Abstract][Full Text] [Related]
28. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983 [TBL] [Abstract][Full Text] [Related]
29. Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting. Druyts EF; Yip B; Lima VD; Burke TA; Lesovski D; Fernandes KA; McInnes CW; Rustad CA; Montaner JS; Hogg RS HIV Med; 2009 Feb; 10(2):88-93. PubMed ID: 19200171 [TBL] [Abstract][Full Text] [Related]
30. Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. Kamya MR; Semitala FC; Quinn TC; Ronald A; Njama-Meya D; Mayanja-Kizza H; Katabira ET; Spacek LA Afr Health Sci; 2004 Aug; 4(2):94-101. PubMed ID: 15477187 [TBL] [Abstract][Full Text] [Related]
31. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense. Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857 [TBL] [Abstract][Full Text] [Related]
32. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. Kiboneka A; Wangisi J; Nabiryo C; Tembe J; Kusemererwa S; Olupot-Olupot P; Joffres M; Anema A; Cooper CL; Montaner JS; Mills EJ AIDS; 2008 Nov; 22(18):2493-9. PubMed ID: 19005272 [TBL] [Abstract][Full Text] [Related]
33. Frequency and predictors for late start of antiretroviral therapy in primary care clinics, Kampala, Uganda. Sendagire I; Cobelens F; Kambugu A; Konde-Lule J; van der Loeff MS J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e33-9. PubMed ID: 22820807 [TBL] [Abstract][Full Text] [Related]
34. Antiretroviral therapy: unmet need and associated socio-demographic characteristics among HIV-positive women in Haiphong, Vietnam. Nam NT; Bygbjerg IC; Mogensen HO; Rasch V AIDS Care; 2011 Jan; 23(1):1-9. PubMed ID: 21218271 [TBL] [Abstract][Full Text] [Related]
35. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. ; Wandel S; Egger M; Rangsin R; Nelson KE; Costello C; Lewden C; Lutalo T; Ndyanabo A; Todd J; Van der Paal L; Minga A; Zwahlen M Sex Transm Infect; 2008 Aug; 84 Suppl 1(Suppl_1):i31-i36. PubMed ID: 18647863 [TBL] [Abstract][Full Text] [Related]
36. Screening HIV-infected adults in Malawi for anaemia: impact on eligibility for antiretroviral therapy. Page ID; McKew SJ; Kudzala AG; Fullwood C; van Oosterhout JJ; Bates I Int J STD AIDS; 2013 Jun; 24(6):449-53. PubMed ID: 23970747 [TBL] [Abstract][Full Text] [Related]
37. CD4 testing at clinics to assess eligibility for antiretroviral therapy. Lumala R; van den Akker T; Metcalf CA; Diggle E; Zamadenga B; Mbewa K; Akkeson A Malawi Med J; 2012 Jun; 24(2):25-8. PubMed ID: 23638266 [TBL] [Abstract][Full Text] [Related]
38. 'Test and Treat' Among Women at High Risk for HIV-infection in Kampala, Uganda: Antiretroviral Therapy Initiation and Associated Factors. Mayanja Y; Kamacooko O; Bagiire D; Namale G; Kaleebu P; Seeley J AIDS Behav; 2018 Mar; 22(3):1053-1061. PubMed ID: 29127534 [TBL] [Abstract][Full Text] [Related]
39. Assessment of the patient flow at the infectious diseases institute out-patient clinic, Kampala, Uganda. Colebunders R; Bukenya T; Pakker N; Smith O; Boeynaems V; Waldron J; Muganga AM; Twijukye C; McAdam K; Katabira E AIDS Care; 2007 Feb; 19(2):149-51. PubMed ID: 17364392 [TBL] [Abstract][Full Text] [Related]
40. Use of dental care services among adolescents living with HIV on antiretroviral treatment in Kampala, Uganda: a cross-sectional study. Nakyonyi MG; Birungi N; Mwesigwa CL; Åstrøm AN BMC Oral Health; 2024 Jun; 24(1):654. PubMed ID: 38835044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]